4.Neonatal Poland-Moebius syndrome in a case.
Shan-hua HUANG ; Li GUO ; Yuan-zong SONG
Chinese Journal of Pediatrics 2008;46(9):718-719
5.Hereditary hyperhomocysteinemia: a case report.
Li GUO ; Bing-xiao LI ; Yuan-zong SONG
Chinese Journal of Pediatrics 2010;48(7):547-548
Child
;
Humans
;
Hyperhomocysteinemia
;
genetics
;
Male
7.A case report of Alagille syndrome.
Chinese Journal of Contemporary Pediatrics 2010;12(12):1005-1007
8.Expression of Claudin-5 and ZO-1 in Early Brain Injury after Subarachnoid Hemorrhage in Rats
Duo CHEN ; Jiangwei YUAN ; I_ei SONG ; Xiangtai WEI ; Junhong GUAN ; Yunhui LIU ; Zhihong ZONG
Journal of China Medical University 2010;(9):713-716
Objective Aimed to clarify the molecular mechanism after subarachnoid hemorrhage (SAH) by investigating the expression of tight junction protein Claudin-5 and ZO-1 and the effects of SP600125 on them. Methods Seventy-five male Sprague Dawley rats (300 to 350 g) were randomly divided into sham,SAH,SAH + DMSO (dimethyl sufoxide) solution,SAH +SP600125 (C-Jun N-terminal kinase inhibitor)10 mg/kg,and SAH +SP600125 30 mg/kg groups. The standard endovaseular perforation was performed to produce experimental SAH. The JNK inhibitor SP600125 was intraperitoneally administered at 1 hour before and 6 hours after SAH. Results At 24 hours after SAH,signs of microvessels injury were observed in brain cortex. Compared with the sham group,expression of Claudin-5 and ZO-1 was sig- nificantly decreased (P 〈 0.05 ). JNK inhibitior SP600125 suppressed the decrease of Claudin-5 and ZO-1 expression, attenuated blood-brain barrier disruption in rats after SAH. Conclusions The blood-brain barrier disruption is an important mechanism of early brain injury after SAH. JNK inhibitor SP600125 improves neurological outcomes and provides neuropmtecfion against acute events after SAH such as bloodbrain barrier disruption and cell apoptosis.
10.Selective Screening of Inborn Errors of Metabolism by Urease Pretreatment-Gas Ch romatography-Mass Spectrometry:Pilot Study of 327 Patients at High Risk
yuan-zong, SONG ; ting, ZHANG ; chun-hua, ZHANG ; zi-neng, WANG
Journal of Applied Clinical Pediatrics 1986;0(02):-
Objective The purpose of this paper is to screen inborn errors of meta bolism (IEM) by analyzing urinary components, so as to provide laboratory guide for their diagnosis and therapy.Methods Urine samples of patients suspected to have IEM were collec- ted.Urea was de compo sed with urease and n-heptadecanoic acid was added as internal standard.Protein was denatured with ethanol and precipitate was removed by centrifugation,dried b y evaporation, the residue was trimethylsilylly derivatized with BSTFA/TMCS,and then analyzed with GC-MS for quantification of organic acids, amino acids,suga rs, polyols, purines and pyrimidines, simultaneously. This procedure is denom inated as urease pretreatment-gas chromatography-mass spectrometry (UP-GC-MS) internationally.Results Urinary samples of 327 patients from 6 provinces, cities and autonomous regions were analyzed,and 16 kinds of 27 cases of IEM were screened out with a positiv e rate of 8.26%,among which there were 3 cases of hyperphenylalaninemia,3 cases of glyceroluria,3 cases of Leigh syndrome, 2 cases of propionic acidemia, 2 case s of methylmalonic aciduria, 2 cases of von Gierke′s disease, 2 cases of fructo se-1,6-diphosphatase deficiency, 2 cases of fructosuria, 1 cases of multiple car boxylase deficiency, 1 cases of glutaric acidemia typeⅠ, 1 cases of maple sy rup urine disease, 1 cases of hyperglycinemia, 1 cases of 3-aminoisobutyric acid uria,1 cases of adult-onset typeⅡcitrullinemia,1 cases of galactosemia and 1 ca ses of Fanconi′s syndrome.Several IEM patients above had died,but satisfactory therapeutic effects had been achieved in some diseases,in cluding multiple carboxylase deficiency,methylmalonic aciduria and galactosemia. Other patients′ condition remained to be followed up.Conclusion Analysis of urinary components by UP-GC-MS provides a valuable tool for screenin g of IEM and the results will help to provide effective diagnostic and therapeut ic guide for the patients. J Appl Clin Pediatr,2005,20(2):142-144